Industry-Sponsored Research Week
University-Industry Engagement Advisor

Johns Hopkins inks five-year master collaboration agreement for psychedelics research


By David Schwartz
Published: August 24th, 2021

Johns Hopkins University School of Medicine has signed a five-year master research agreement with Mydecine Innovations Group to study a variety of medicinal use cases for psychedelic agents. A major focus of the work will be examining treatments for mental health and addiction disorders, led by Professor of Psychiatry and Behavioral Sciences Matthew W. Johnson, PhD. The Johns Hopkins Behavioral Pharmacology Research Unit has extensive experience conducting clinical research related to therapeutic use of psychedelics.  

“We are excited to expand on the current work we are conducting with Dr. Matt Johnson and his team at JHU in regards to smoking cessation to include numerous other projects over the next five years,” said Mydecine CEO Josh Bartch. “The researchers at JHU have proven their incredible depth of knowledge in the field.”

“The long-term potential of this research agreement is captivating for us here at Mydecine,” added Chief Scientific Officer and Co-Founder of Mydecine Rob Roscow. “It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.”

The company is betting on the ability of psychedelic compounds to address long-entrenched and widespread addictions including to nicotine. “Despite the recent attention to opiate and dependance on other illicit substances, we sometimes forget about the incredible burden that nicotine dependence has on our societies,” said Dr. Rakesh Jetly, Mydecine’s Chief Medical Officer. “According to the CDC, cigarette smoking is the leading cause of preventable disease and death in the United States, killing more than 480,000 Americans each year. Despite all the public education and dire warnings, cigarette smoking remains one of the most difficult addiction to treat and contributes to more deaths than all the other substances combined, making research like this vital.”

Source: GlobeNewswire

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment